European Trial of Immunosuppression in SPK Tx

Back to Search
Print
Bookmark Trial

NCT00140543

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Universitätsklinik
Innsbruck, , 6020, Austria
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Type 1 Diabetes Mellitus, Diabetic Nephropathy
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-55 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. Male or female patients, of 18 to 55 years of age, with end-stage, C-peptide-negative, Type 1-diabetic nephropathy.

2. Female patients of childbearing age must have a negative pregnancy test and must agree to maintain effective birth control practice throughout the study period (3 years).

3. Patient must have signed the Patient Informed Consent Form.

4. Patient must receive a primary simultaneous pancreas/kidney (SPK) cadaveric transplant, with either intestinal or bladder and either portal or systemic venous drainages.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


1. Patient is pregnant or breastfeeding.


2. Patient is allergic or intolerant to Mycophenolate Mofetil, Sirolimus, Tacrolimus or
other macrolides, or any compounds structurally related to these compounds.


3. Patient has a positive T-cell crossmatch on the most recent serum specimen.


4. Patient is known for active liver disease or has significant liver disease, defined by
ASAT and ALAT serum levels greater than 3 times the upper limit of normal.


5. Patient has malignancy or history of malignancy, with the exception of adequately
treated localised squamous cell or basal cell carcinoma, without recurrence.


6. Patient has been included in another clinical trial protocol for any investigational
drug within 4 weeks prior to randomisation.


7. Patient has any form of substance abuse, psychiatric disorder or condition, which, in
the opinion of the investigator, may invalidate communication.


8. Patient receives a SPK transplant from a living donor, or receives segmental
pancreatic transplant, or a previous kidney transplant alone.


9. Pancreatic duct occlusion technique .


10. Donor is older than 55 years of age.


-

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Type 1 Diabetes Mellitus, Diabetic NephropathyEuropean Trial of Immunosuppression in SPK Tx
NCT00140543
  1. Innsbruck,
  2. Brussels,
  3. Gent,
  4. Leuven,
  5. Prague,
  6. Berlin,
  7. Bochum-Langendreer,
  8. Frankfurt am Main,
  9. Freiburg,
  10. Munich,
  11. Munich,
  12. Tel Aviv,
  13. Barcelona,
  14. Geneva,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE European Trial of Immunosuppression in SPK Tx
Official Title  ICMJE A European Multicenter Open-Label Randomised Trial to Evaluate the Efficacy and Safety of Sirolimus and Tacrolimus Compared to MMF and Tacrolimus With Short-Course Induction Therapy, Short-Term Steroids Application in De Novo SPK Transplanted Diabetic Patients
Brief Summary
  1. To determine and compare the efficacy of Tacrolimus/Rapa versus Tacrolimus/MMF-based immunosuppression (in conjunction with initial short-term steroids and polyclonal antibody administration) in Type 1-diabetic patients undergoing simultaneous pancreas/kidney allograft transplantation.
  2. To evaluate the safety of Tacrolimus/Rapa versus Tacrolimus/MMF in terms of drug-related complications and overimmunosuppression-associated complications, particularly under monitoring of the pharmacokinetic profile of all drugs administered.
Detailed Description This will be a controlled, randomised study, to be performed in 15-20 pancreas transplantation centers throughout Europe. Patients will be randomised into one of two treatment groups. Group 1 will receive Tacrolimus and Mycophenolate Mofetil (= best group in EuroSPK001 trial). Group 2 will receive Tacrolimus and Sirolimus. Both groups will receive in association short-term corticosteroids and polyclonal antibody preparation. Patients will be randomly assigned to one of the 2 treatment groups in a 1:1 ratio before transplantation. The study will last 3 years, with a first interim analysis of the data at 6 months and a complete analysis at 1 year.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Diabetes Mellitus, Type 1
  • Diabetic Nephropathy
Intervention  ICMJE Drug: sirolimus versus mycophenolate mofetil
Study Arms  ICMJE Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Unknown status
Enrollment  ICMJE
 (submitted: August 31, 2005)		228
Original Enrollment  ICMJE Same as current
Study Completion Date  ICMJE April 2008
Primary Completion Date Not Provided
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Male or female patients, of 18 to 55 years of age, with end-stage, C-peptide-negative, Type 1-diabetic nephropathy.
  2. Female patients of childbearing age must have a negative pregnancy test and must agree to maintain effective birth control practice throughout the study period (3 years).
  3. Patient must have signed the Patient Informed Consent Form.
  4. Patient must receive a primary simultaneous pancreas/kidney (SPK) cadaveric transplant, with either intestinal or bladder and either portal or systemic venous drainages.

Exclusion Criteria:

  1. Patient is pregnant or breastfeeding.
  2. Patient is allergic or intolerant to Mycophenolate Mofetil, Sirolimus, Tacrolimus or other macrolides, or any compounds structurally related to these compounds.
  3. Patient has a positive T-cell crossmatch on the most recent serum specimen.
  4. Patient is known for active liver disease or has significant liver disease, defined by ASAT and ALAT serum levels greater than 3 times the upper limit of normal.
  5. Patient has malignancy or history of malignancy, with the exception of adequately treated localised squamous cell or basal cell carcinoma, without recurrence.
  6. Patient has been included in another clinical trial protocol for any investigational drug within 4 weeks prior to randomisation.
  7. Patient has any form of substance abuse, psychiatric disorder or condition, which, in the opinion of the investigator, may invalidate communication.
  8. Patient receives a SPK transplant from a living donor, or receives segmental pancreatic transplant, or a previous kidney transplant alone.
  9. Pancreatic duct occlusion technique .

  10. Donor is older than 55 years of age.

    -

Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years to 55 Years   (Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Austria,   Belgium,   Czech Republic,   Germany,   Israel,   Spain,   Switzerland
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00140543
Other Study ID Numbers  ICMJE EUROSPK002
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Not Provided
Study Sponsor  ICMJE EUROSPK Study Group
Collaborators  ICMJE
  • Fujisawa GmbH
  • Hoffmann-La Roche
  • Wyeth is now a wholly owned subsidiary of Pfizer
  • Neovii Biotech
  • Genzyme, a Sanofi Company
Investigators  ICMJE
Study Chair:Jean-Paul Squifflet, MD,PhDSPEAKER FOR THE EUROSPK STUDY GROUP
PRS Account EUROSPK Study Group
Verification Date August 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP